Life Sciences Market Research Report
Report Filter Reset All
Sort By Price
Published Date
Category
Publishers
Report Type
Continents
Regions
Global Acral Lentiginous Melanoma Treatment Market Insights, Forecast to 2025
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog ...
$3,900.00 22 May, 2019 | QYResearch
Global Acral Lentiginous Melanoma Treatment Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing ...
Global Acral Lentiginous Melanoma Market Insights, Forecast to 2025
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog ...
$3,900.00 22 May, 2019 | QYResearch
Global Acral Lentiginous Melanoma Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing ...
Global Sandostatin LAR Market Insights, Forecast to 2025
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor ...
$3,900.00 22 May, 2019 | QYResearch
Global Sandostatin LAR Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent ...
Global Pasireotide Market Insights, Forecast to 2025
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surg...
$3,900.00 22 May, 2019 | QYResearch
Global Pasireotide Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligibl...
Global Signifor Market Insights, Forecast to 2025
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgica...
$3,900.00 22 May, 2019 | QYResearch
Global Signifor Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible f...
Global Lanreotide Market Insights, Forecast to 2025
Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The globa...
$3,900.00 22 May, 2019 | QYResearch
Global Lanreotide Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome...
Global Somatuline Market Insights, Forecast to 2025
Somatuline is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Soma...
$3,900.00 22 May, 2019 | QYResearch
Global Somatuline Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Somatuline is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The g...
Global Sandostatin LAR Drugs Market Insights, Forecast to 2025
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor ...
$3,900.00 22 May, 2019 | QYResearch
Global Sandostatin LAR Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent ...
Global Pasireotide Drugs Market Insights, Forecast to 2025
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surg...
$3,900.00 22 May, 2019 | QYResearch
Global Pasireotide Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligibl...
Global Signifor Drugs Market Insights, Forecast to 2025
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgica...
$3,900.00 22 May, 2019 | QYResearch
Global Signifor Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Signifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible f...
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
